Tim Walbert, Horizon CEO (via YouTube)

Hori­zon low­ers ex­pec­ta­tions for Te­pez­za and ad­justs its strat­e­gy for the year ahead

One of Hori­zon Ther­a­peu­tics’ top sell­ers isn’t per­form­ing as well as ex­pect­ed, CEO Tim Wal­bert re­vealed on Wednes­day’s Q2 call, lead­ing the phar­ma com­pa­ny to switch up its strat­e­gy.

While Wal­bert not­ed a 13% in­crease in sales last quar­ter, to­tal­ing $876.4 mil­lion, the chief ex­ec­u­tive low­ered his full-year ex­pec­ta­tions for the thy­roid eye dis­ease (TED) drug Te­pez­za. While the drug was ini­tial­ly ex­pect­ed to see a per­cent­age growth in the mid-30s, Wal­bert now an­tic­i­pates a sales growth in the high-teens.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.